Granted Patent B2

US 12,521,440 · App. 19/048,594 · Granted Jan 13, 2026

Inventors: Changxin Huo (Beijing, CN); Hexiang Wang (Beijing, CN); Ruipeng Qi (Beijing, CN); Zhiwei Wang (Beijing, CN); Huaqing Liu (Beijing, CN)

Assignee: BeOne Medicines I GmbH

A61K47/55A61K47/545

Abstract

Claims (22)

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof; wherein

the

moiety is

the moiety is

Cy1a is

wherein Cy1a is optionally substituted with R 9 ;

Cy1b is

wherein Cy1b is optionally substituted with R 10 , *1b refers to the position attached to the

moiety and ** 1b refers to the position attached to the

moiety;

L a , L c , and L d are each a single bond;

L b is a single bond, —CO—, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —;

each of occurrence, R 9 and R 10 are each independently hydrogen or C 1-8 alkyl,

p3 and p4 are each 1;

s1 is 1;

s2 is 0 or 1; and

s3 is 0.

2 . The compound of claim 1 , wherein s2 is 0, or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 2 , wherein L b is —CH 2 CH 2 —, or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 , wherein L b is —CH 2 CH 2 —, or a pharmaceutically acceptable salt thereof.

5 . A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof.

Assignments (4)

Priority Claims (1)

Continuity (3)

References Cited (134)